Paediatric cardiomyopathy and heart failure are distinct but frequently associated conditions, which have a high mortality. Traditional medical therapy has evolved to incorporate newer classes of heart failure drugs, although the evidence to support efficacy in children is limited. This perspective article discusses the rationale, benefits and limitations of the various classes of drug therapy used in paediatric heart failure due to cardiomyopathy or congenital heart disease. Controversies in management and challenges for future development are highlighted.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2011.06.006DOI Listing

Publication Analysis

Top Keywords

heart failure
16
heart
5
pharmacologic therapy
4
therapy heart
4
failure
4
failure children
4
children special
4
special series
4
series paediatric
4
paediatric pharmacology
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!